Masashi Kasajima

Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma

Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri et autres

jp (code pays fourni par la source)

The Glasgow Prognostic Score Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations Who Are Treated with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Yuki Akazawa, Satoshi Igawa, Kaori Yamada, Hiroki Yamamoto et autres

INTRODUCTION: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. Information …

jp (code pays fourni par la source)

The Glasgow prognostic score predicts survival in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations who are treated with tyrosine kinase inhibitors

Yuki Akazawa, Satoshi Igawa, Kaori Yamada, Hiroki Yamamoto et autres

Abstract Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) with sensitive EGFR mutations. The Glasgow prognostic score (GPS) is an inflammation-assessing score based on C-reactive protein and albumin concentrations. …

jp (code pays fourni par la source)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer

Masashi Kasajima, Satoshi Igawa, Hiroya Manaka, Kaori Yamada et autres

INTRODUCTION: Predictors of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors. METHODS: Eighty patients treated with pembrolizumab …

jp (code pays fourni par la source)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

Hideki Terai, Kenzo Soejima, Asanao Shimokawa, Hidehito Horinouchi et autres

Introduction Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirmative data obtained through postmarketing all-case surveillance (PMACS), which was …

jp (code pays fourni par la source)

Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma

Hiroya Manaka, Satoshi Igawa, Michiko Yamamoto, Akito Oguri et autres

Abstract Background: Thymic carcinoma is a very rare neoplasm for which no optimal chemotherapeutic regimen has been established to date. Hence, we performed this study to investigate the efficacy and safety of carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel as a first-line regimen for …

jp (code pays fourni par la source)

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

Satoshi Igawa, Tomoya Fukui, Masashi Kasajima, Taihei Ono et autres

jp (code pays fourni par la source)

A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Satoshi Igawa, Masashi Kasajima, Taihei Ono, Takahiro Ozawa et autres

Background: The clinical outcomes of elderly patients with EGFR -mutated non-small cell lung cancer (NSCLC) who are treated with osimertinib have not been sufficiently evaluated. This study aimed to assess the efficacy and safety of osimertinib in elderly chemotherapy-naive patients with NSCLC …

jp (code pays fourni par la source)

First-line Osimertinib for Poor Performance Status Patients With EGFR Mutation-positive Non-small Cell Lung Cancer: A Prospective Observational Study

Satoshi Igawa, Tomoya Fukui, Masashi Kasajima, Taihei Ono et autres

jp (code pays fourni par la source)

P76.53 Impact of Neutrophil-to-Lymphocyte Ratio in Patients with EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibitors

Takaaki Ono, Satoshi Igawa, Koudai Yamada, Akira Kameda et autres

jp (code pays fourni par la source)

P76.55 Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC

Satoshi Igawa, Takaaki Ono, Masashi Kasajima, Koudai Yamada et autres

jp (code pays fourni par la source)

Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer

Satoshi Igawa, Taihei Ono, Masashi Kasajima, Hideaki Manabe et autres

Purpose: Amrubicin (AMR) is an anticancer drug for patients with relapsed small-cell lung cancer (SCLC). However, the efficacy of AMR in elderly patients with relapsed SCLC after chemotherapy by carboplatin plus etoposide (CE) has not been sufficiently evaluated. Patients and Methods: The …

jp (code pays fourni par la source)